Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Accumulated Expenses (2022 - 2024)

Inmune Bio (INMB) has disclosed Accumulated Expenses for 3 consecutive years, with $139000.0 as the latest value for Q2 2024.

  • Quarterly Accumulated Expenses rose 1444.44% to $139000.0 in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $139000.0 through Jun 2024, up 1444.44% year-over-year, with the annual reading at $35000.0 for FY2023, 288.89% up from the prior year.
  • Accumulated Expenses hit $139000.0 in Q2 2024 for Inmune Bio, up from $56000.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $139000.0 in Q2 2024 to a low of $9000.0 in Q4 2022.
  • Historically, Accumulated Expenses has averaged $48000.0 across 3 years, with a median of $35000.0 in 2023.
  • Biggest five-year swings in Accumulated Expenses: soared 288.89% in 2023 and later surged 1444.44% in 2024.
  • Year by year, Accumulated Expenses stood at $9000.0 in 2022, then skyrocketed by 288.89% to $35000.0 in 2023, then skyrocketed by 297.14% to $139000.0 in 2024.
  • Business Quant data shows Accumulated Expenses for INMB at $139000.0 in Q2 2024, $56000.0 in Q1 2024, and $35000.0 in Q4 2023.